$CNBX
CNBX Pharmaceuticals Inc. Stock $cnbx

$cnbx Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000168316823008557 Filed on November 30, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2023
Revenue	$89.44K	$100.0K	$410.2K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$148.9K	$168.3K	$911.2K
YoY Change	-47.54%	-46.54%	-49.0%
% of Gross Profit
Research & Development	$112.4K	$93.24K	$431.6K
YoY Change	78.76%	-43.01%	-63.53%
% of Gross Profit
Depreciation & Amortization	$39.46K	$38.49K	$162.1K
YoY Change	-8.62%	-18.61%	-18.37%
% of Gross Profit
Operating Expenses	$261.3K	$261.5K	$1.342M
YoY Change	-24.64%	-45.33%	-54.59%
Operating Profit	-$171.9K		-$931.4K
YoY Change	-50.43%		-68.47%
Interest Expense	-$6.620K	-$412.1K	-$2.730M
YoY Change	-39.15%	30422.96%	5703.57%
% of Operating Profit
Other Income/Expense, Net	-$6.623K		$52.62K
YoY Change	-39.12%		-93.16%
Pretax Income	-$178.5K	-$573.6K	-$3.710M
YoY Change	-50.09%	19.56%	-0.36%
Income Tax
% Of Pretax Income
Net Earnings	-$178.5K	-$573.6K	-$3.710M
YoY Change	-50.09%	19.56%	-0.35%
Net Earnings / Revenue	-199.61%	-573.55%	-904.57%
Basic Earnings Per Share	$0.00		-$0.42
Diluted Earnings Per Share	$0.00	-$0.02	-$0.42
COMMON SHARES
Basic Shares Outstanding	28.31M shares	17.03M shares	8.825M shares
Diluted Shares Outstanding	27.76M shares		8.825M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$81.65K	$129.7K	$130.0K
YoY Change	278.01%	10.36%	10.62%
Cash & Equivalents	$81.65K	$129.7K	$130.0K
Short-Term Investments
Other Short-Term Assets	$69.29K	$94.61K	$90.00K
YoY Change	-11.27%	17.14%	11.43%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$150.9K	$224.3K	$220.0K
YoY Change	51.41%	13.12%	10.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$236.5K	$274.7K	$270.0K
YoY Change	-39.92%	-37.1%	-38.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Assets
YoY Change
Total Long-Term Assets	$236.5K	$274.7K	$280.0K
YoY Change	-53.62%	-55.17%	-54.31%
TOTAL ASSETS
Total Short-Term Assets	$150.9K	$224.3K	$220.0K
Total Long-Term Assets	$236.5K	$274.7K	$280.0K
Total Assets	$387.4K	$499.0K	$500.0K
YoY Change	-36.44%	-38.48%	-38.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$245.7K	$335.9K	$340.0K
YoY Change	-58.84%	-27.15%	-26.27%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$1.314M	$1.344M	$1.340M
YoY Change	-25.47%	-23.6%	-23.81%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.482M	$2.516M	$2.520M
YoY Change	-3.93%	2.98%	3.13%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.482M	$2.516M	$2.520M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.482M	$2.516M	$2.520M
YoY Change	-3.93%	2.98%	3.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$24.44M	-$24.26M
YoY Change	16.89%	18.06%
Common Stock	$2.831K	$2.261K
YoY Change	2183.06%	1723.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.095M	-$2.017M	-$2.020M
YoY Change
Total Liabilities & Shareholders Equity	$387.4K	$499.0K	$500.0K
YoY Change	-36.44%	-38.48%	-38.36%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2023
OPERATING ACTIVITIES
Net Income	-$178.5K	-$573.6K	-$3.710M
YoY Change	-50.09%	19.56%	-0.35%
Depreciation, Depletion And Amortization	$39.46K	$38.49K	$162.1K
YoY Change	-8.62%	-18.61%	-18.37%
Cash From Operating Activities	-$71.85K	$20.52K	-$112.5K
YoY Change	-25.09%	-113.72%	-93.3%
INVESTING ACTIVITIES
Capital Expenditures	$1.200K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$20.00K
YoY Change		-100.0%	-25.62%
Cash From Investing Activities	-$1.196K	$0.00	$24.70K
YoY Change		-100.0%	-2.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$24.99K	65.03K	$100.0K
YoY Change		-56.61%	-74.35%
NET CHANGE
Cash From Operating Activities	-$71.85K	20.52K	-$112.5K
Cash From Investing Activities	-$1.196K	0.000	$24.70K
Cash From Financing Activities	$24.99K	65.03K	$100.0K
Net Change In Cash	-$48.05K	85.55K	$12.18K
YoY Change	-49.9%	227.9%	-100.96%
FREE CASH FLOW
Cash From Operating Activities	-$71.85K	$20.52K	-$112.5K
Capital Expenditures	$1.200K	$0.00	$0.00
Free Cash Flow	-$73.05K	$20.52K	-$112.5K
YoY Change		-113.83%	-93.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001343009
CY2022	CNBX	Postsplit Adjustment PostsplitAdjustment		usd
CY2023	CNBX	Expiration Of Warrants ExpirationOfWarrants		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-08-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--08-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-52403
CY2023	dei	Entity Registrant Name EntityRegistrantName	CNBX PHARMACEUTICALS INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-3373669
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	#3 Bethesda Metro Center
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 700
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Bethesda
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20814
CY2023	dei	City Area Code CityAreaCode	877
CY2023	dei	Local Phone Number LocalPhoneNumber	424-2429
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $.0001 Par Value
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Public Float EntityPublicFloat	437714	usd
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28311352	shares
CY2023	dei	Auditor Firm AuditorFirmId	6629
CY2023	dei	Auditor Name AuditorName	Weinstein International. C.P.A.
CY2023	dei	Auditor Location AuditorLocation	Tel - Aviv, Israel
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	129696	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	117515	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	94612	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	80772	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	224308	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	198287	usd
CY2023Q3	us-gaap	Investments Investments	0	usd
CY2022Q3	us-gaap	Investments Investments	176087	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	274731	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	436792	usd
CY2023Q3	us-gaap	Assets Assets	499039	usd
CY2022Q3	us-gaap	Assets Assets	811166	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	335915	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	461128	usd
CY2023Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1343584	usd
CY2022Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1758702	usd
CY2023Q3	CNBX	Due To Related Party DueToRelatedParty	836829	usd
CY2022Q3	CNBX	Due To Related Party DueToRelatedParty	223645	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2516328	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2443475	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22611352	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22611352	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1238659	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1238659	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	2261	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	124	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22239652	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	18031869	usd
CY2023Q3	us-gaap	Other Additional Capital OtherAdditionalCapital	0	usd
CY2022Q3	us-gaap	Other Additional Capital OtherAdditionalCapital	3459510	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2574846	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24259202	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-20548968	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-2017289	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-1632311	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	499039	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	811166	usd
CY2023	us-gaap	Revenues Revenues	410165	usd
CY2022	us-gaap	Revenues Revenues	29958	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	431565	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1183281	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	909980	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1800647	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	1341545	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	2983928	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-931380	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2953970	usd
CY2023	CNBX	Capital Gain Loss CapitalGainLoss	-2726231	usd
CY2022	CNBX	Capital Gain Loss CapitalGainLoss	12800	usd
CY2023	CNBX	Financial Loss Net FinancialLossNet	-52623	usd
CY2022	CNBX	Financial Loss Net FinancialLossNet	-782080	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3710234	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3723250	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-669131	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3710234	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4392381	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.59
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.59
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8824636	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8824636	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1222641	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1222641	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3710234	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3723250	usd
CY2023	us-gaap	Depreciation Depreciation	162061	usd
CY2022	us-gaap	Depreciation Depreciation	198527	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	180480	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	728869	usd
CY2023	CNBX	Interest On Convertible Loan InterestOnConvertibleLoan	54811	usd
CY2022	CNBX	Interest On Convertible Loan InterestOnConvertibleLoan	722236	usd
CY2023	CNBX	Capital Loss Gain CapitalLossGain	-2726232	usd
CY2022	CNBX	Capital Loss Gain CapitalLossGain	12800	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	13840	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-123603	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	487969	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	283623	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-112521	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1679192	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	26885	usd
CY2023	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	24702	usd
CY2022	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	0	usd
CY2023	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	-0	usd
CY2022	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	1656	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24702	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	25229	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	100000	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	389858	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	100000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	389858	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	12181	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1264105	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-4853	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117515	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1386473	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	129696	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117515	usd
CY2023	CNBX	Exercise Of Convertible Loan To Shares Of Common Stock. ExerciseOfConvertibleLoanToSharesOfCommonStock.	569930	usd
CY2022	CNBX	Exercise Of Convertible Loan To Shares Of Common Stock. ExerciseOfConvertibleLoanToSharesOfCommonStock.	225286	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	1805915	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	728869	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	225286	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-669131	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3723250	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-1632311	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	180480	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	569930	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2574846	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3710234	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-2017289	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3710234	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24259202	usd
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zdGpwSbTPWNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86C_zBdGvHpwOwnc">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the accompanying financial statements include the amortization period for intangible assets, impairment valuation of intangible assets, valuation of share-based payments and the valuation allowance on deferred tax assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zAVF42egYI56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_z7MsdL5Qgk93">Concentration of Credit Risk</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company places its cash and cash equivalents with high credit quality financial institutions. There is Federal Deposit Insurance on the Company’s U.S. bank accounts for up to $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20230831_zsXZ4YmmMrXh" title="Federal deposit insurance">250,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023	us-gaap	Depreciation Depreciation	162061	usd
CY2022	us-gaap	Depreciation Depreciation	198527	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_848_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zVNcwYGTkZXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_864_z3ConaoVnQr4">Reclassification</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
CY2023Q3	us-gaap	Bank Acceptances Executed BankAcceptancesExecuted	5000	usd
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1:120
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5984924	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5381031	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5984924	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5381031	usd
CY2023Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	603893	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1055107	usd
CY2023Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	24259202	usd
CY2022Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	24200	usd
CY2022Q4	CNBX	Capital Loss CapitalLoss	2726231	usd
CY2023	us-gaap	Labor And Related Expense LaborAndRelatedExpense	461375	usd
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense	379618	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	180480	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	728870	usd
CY2023	us-gaap	Legal Fees LegalFees	149108	usd
CY2022	us-gaap	Legal Fees LegalFees	443851	usd
CY2023	us-gaap	General Insurance Expense GeneralInsuranceExpense	68278	usd
CY2022	us-gaap	General Insurance Expense GeneralInsuranceExpense	93192	usd
CY2023	us-gaap	Marketing Expense MarketingExpense	1223	usd
CY2022	us-gaap	Marketing Expense MarketingExpense	15977	usd
CY2023	us-gaap	Other General Expense OtherGeneralExpense	49516	usd
CY2022	us-gaap	Other General Expense OtherGeneralExpense	139139	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	909980	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1800647	usd
CY2023	us-gaap	Interest Expense Borrowings InterestExpenseBorrowings	1174	usd
CY2022	us-gaap	Interest Expense Borrowings InterestExpenseBorrowings	1273	usd
CY2023	CNBX	Loss Gain From Convertible Loan Valuation LossGainFromConvertibleLoanValuation	54810	usd
CY2022	CNBX	Loss Gain From Convertible Loan Valuation LossGainFromConvertibleLoanValuation	722236	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3361	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	58571	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	52623	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	782080	usd

Files In Submission

Name	View Source	Status
0001683168-23-008557-index-headers.html	Edgar Link	pending
0001683168-23-008557-index.html	Edgar Link	pending
0001683168-23-008557.txt	Edgar Link	pending
0001683168-23-008557-xbrl.zip	Edgar Link	pending
cnbx-20230831.xsd	Edgar Link	pending
cnbx_ex3101.htm	Edgar Link	pending
cnbx_ex3102.htm	Edgar Link	pending
cnbx_ex3201.htm	Edgar Link	pending
cnbx_ex3202.htm	Edgar Link	pending
cnbx_i10k-083123.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
image_015.jpg	Edgar Link	pending
image_016.jpg	Edgar Link	pending
image_017.jpg	Edgar Link	pending
image_018.jpg	Edgar Link	pending
image_019.gif	Edgar Link	pending
image_019.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
cnbx-20230831_cal.xml	Edgar Link	unprocessable
cnbx-20230831_pre.xml	Edgar Link	unprocessable
cnbx-20230831_def.xml	Edgar Link	unprocessable
cnbx-20230831_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cnbx_i10k-083123_htm.xml	Edgar Link	completed
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CNBX
CNBX Pharmaceuticals Inc. Stock $cnbx

2023 Q4 Form 10-K Financial Statement

#000168316823008557 Filed on November 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNBX CNBX Pharmaceuticals Inc. Stock $cnbx

2023 Q4 Form 10-K Financial Statement

#000168316823008557 Filed on November 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNBX
CNBX Pharmaceuticals Inc. Stock $cnbx